1[1]Gaine S. Pulmonary hypertension. JAMA, 2000, 284:3160-3168.
2[2]Heath D, Edwards J. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation, 1958, 18:533-547.
3[3]Kidd L, Driscoll D, Gersony W, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation, 1993, 87:138-151.
4[4]Vogel M, Berger F, Kramer A, et al. Incidence of se-condary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart, 1999, 82:30-33.
5[5]Jeffery T K, Morrell N W. Molecular and cellular basis of pulmonary vascular remondeling in pulmonary hypertension. Prog Cardiol Dis, 2002, 45:173-202.
6[6]Geiger R, Berger R M, Hess J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol, 2000, 191:202-207.
7[7]Tuder R M, Cool C D, Yeager M, et al. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med, 2001, 22:405-418.
8[8]Davie N, Haleen S J, Upton P D, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med, 2002, 165:398-405.
9[9]Gries A, Bode C, Peter K, et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation, 1998, 97:1481-1487.
10[10]Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med, 1995, 333:214-221.
9[2]Cantor WJ,Harrison DA,Moussadji JS,et al.Determinants of survival and length of survival in adults with Eisenmenger syndrome[J].Am J Cardiol,1999,84:677-681.
